Tamoxifen decreases human prostate CPK concentration

Publisher Website
Google Scholar
Abstract
Creatine phosphokinase (CPK) was measured in whole prostate tissue of patients with benign prostatic hypertrophy (BPH) who were given Tamoxifen and/or megestrol acetate for seven days prior to transurethral resection of the prostate. Tamoxifen and Tamoxifen plus Megace®, but not Megace® alone, significantly decreased CPK concentrations in whole prostate tissue in comparison to untreated controls, suggesting that CPK is an estrogen‐dependent enzyme in the prostate. CPK concentration was also measured separately in mechanically separated prostate stroma and epithelium. The levels of CPK were 2.19 times higher in stroma than epithelium. This study suggests that CPK may be a marker for estrogen stimulation of the stroma in BPH tissue.